Protara Therapeutics, Inc. — Director's Dealing 2017

Sep 18, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: PROTEON THERAPEUTICS INC (PRTO)
CIK: 0001359931
Period of Report: 2017-09-14

Reporting Person: NOYES TIMOTHY P (Director, President and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-09-14	Common Stock	D	4854	$1.454	Disposed	53888	Direct
2017-09-15	Common Stock	D	5146	$1.479	Disposed	48742	Direct

Footnotes

F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 14, 2017.

F2: The selling price of $1.454 is reflective of the weighted average sale price of all transactions reported on this line. The prices for the transactions reported on this line range from $1.425 to $1.475. The reporting person undertakes to provide Proteon Therapeutics, Inc., any security holder of Proteon Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: The selling price of $1.479 is reflective of the weighted average sale price of all transactions reported on this line. The prices for the transactions reported on this line range from $1.475 to $1.50. The reporting person undertakes to provide Proteon Therapeutics, Inc., any security holder of Proteon Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.